Parameter | Base assumptions | Range for sensitivity analysis | Source |
---|---|---|---|
Prevalence of HBsAg among pregnant women | 0.047 | 0.025–0.1 | [3] |
Prevalence of HBeAg among HBsAg positive mothers | 0.116 | 0.05–0.25 | [4] |
Risk of perinatal transmission (HBeAg +) | 0.279 | 0.1–0.6 | [4] |
Risk of perinatal transmission (HBeAg−) | 0.08 | 0.02–0.29 | [4] |
Acute symptomatic cases (for children of HBeAg + mothers) | 0.01 | – | [4] |
Acute symptomatic cases (for children of HBeAg − mothers) | 0.05 | – | [23] |
Fulminant infections among symptomatic cases | 0.001 | – | [15] |
Risk of infant death from fulminant infection | 0.7 | – | [15] |
Risk of infant chronic infection among survivors of fulminant infection | 0.33 | – | [15] |
Risk of chronic HBV infection after perinatal infection | 0.9 | – | [4] |
Chronic HBV infected individuals requiring antiviral treatment (CAH) | 0.25 | – | [20] |
Inactive carriers among individuals with chronic HBV infection | 0.75 | – | [20] |
Annual transition probabilities and disease related mortality | |||
 Inactive carrier to | |||
  CAH | 0.03 | – | [23] |
  Compensated cirrhosis | 0.007 | – | [24] |
  HCC | 0.0006 | – | [24] |
 CAH toa |  |  | [24] |
  Inactive carrier | 0.55 | 0.3–0.7 | [24] |
  Compensated cirrhosis | 0.0024 | 0.0012–0.0036 | [24] |
  HCC | 0.003 | 0.002–0.007 | [24] |
 Compensated cirrhosis to | |||
  Decompensated cirrhosis | 0.035 | – | [23] |
  HCC | 0.033 | – | [23] |
  Regression | 0.24 | – | [24] |
 Decompensated cirrhosis to |  |  |  |
  Disease specific death | 0.28 | – | [23] |
  HCC | 0.15 | – | [23] |
 HCC to | |||
  Disease specific death | 0.29 | – | [23] |
Vaccine effectiveness | 0.72 | 0.6–0.8 | [27] |
Vaccine utilization | 0.5 | 0.1–0.66b | [14] |